This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Tepotinib is a medication that contains Tepotinib as an active agent. The primary benefit of this medication is its ability to slow down or stop the growth and prevent the spread of cancer cells in the body, particularly in patients with non-small cell lung cancer (NSCLC) that has a mutation in the MET gene (surface of certain cancer cells). Tepotinib was approved by the United States Food and Drug Administration (FDA) on February 3, 2021, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation known as MET exon 14 skipping. Patients with an allergy to tepotinib or any of its components should not use this medication.

Mechanism of Action of undefined

In patients with NSCLC and the specific MET mutation, tepotinib has been shown to have an anti-tumor effect, leading to tumor shrinkage and improved disease control. Studies have demonstrated that this medicine can significantly improve progression-free survival (PFS) in patients with NSCLC compared to standard chemotherapy.

Uses of undefined

Tepotinib is used to treat non-small cell lung cancer (NSCLC).

undefined Drug administaration and Dosage available

Take tepotinib exactly as prescribed by your doctor. The recommended dose and dosing schedule may vary depending on your medical condition, age, weight, and other factors. It should be taken with food. Swallow the tablet as a whole with a glass of water. Patients should not chew, crush, or break the tablet, as this may affect the effectiveness of the medication. Avoid doubling the dose to compensate for the missed dose.

Warnings, Precautions and Side Effects of undefined

Warnings

Patients should be aware of some warnings associated with tepotinib use. These warnings include the risk of interstitial lung disease, hepatotoxicity, and hypertension, as well as the potential for severe skin reactions, immune-mediated adverse reactions, cataracts, and renal impairment.

Precautions

Individuals with a history of severe allergic reactions to any tepotinib component should not receive it. Inform your healthcare provider of any pre-existing medical conditions, medications, or supplements you are taking before starting treatment with tepotinib. If you experience any new or worsening symptoms during treatment, such as difficulty breathing, yellowing of the skin or eyes, or vision changes, notify your healthcare provider immediately.

Side Effects

Tepotinib is generally well-tolerated, but it can cause side effects like all medications. The most common side effects include peripheral edema (arm or leg swelling), nausea, diarrhea, fatigue, musculoskeletal pain, and dyspnea (shortness of breath). More serious side effects may include interstitial lung disease, and hepatotoxicity (liver damage).

Word Of Advice

If you have been prescribed tepotinib, it is important to follow your doctor's instructions carefully. Suppose you experience any unusual symptoms or side effects while taking tepotinib, such as fever, persistent cough, difficulty breathing, abdominal pain, or signs of liver dysfunction. In such a case, you should contact your doctor immediately. Do not stop medication without first consulting your doctor, as this may affect the effectiveness of the medication and your treatment outcomes. Pregnant and breastfeeding women should consult with a healthcare provider before taking it. Avoid close contact with an infected person, as this medication lowers the immune system. Always maintain a healthy and balanced diet to support your overall health and well-being.

Frequently Asked Question

References

  1. Merck Limited, Electronic Medicines Compendium (EMC), [Revised on 25 May 2022] [Accessed on 10th May 2023], https://www.medicines.org.uk/emc/product/12970/smpc 
  2. EMD Serono, Inc., US Food & Drug Administration, [Revised on 3rd Feb 2021] [Accessed on 10th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf
  3. Goodman & Gilman's the pharmacological basis of Therapeutics, 13th Edition., 2018, 1549-1674

Disclaimer

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.